VolitionRx (NYSE:VNRX) Stock Price Down 4.3% - Here's Why

Key Points

• VolitionRx's stock price fell by 4.3% to $0.64 amid increased trading volume, marking a decline from its previous close of $0.67.
• Analysts have set various price targets for VolitionRx, with Jones Trading upgrading to a "strong-buy" at $3.00, while others have issued a "sell" rating, reflecting mixed sentiments in the market.
• Insider trading activity was noted, with CEO Cameron John Reynolds and Director Guy Archibald Innes each purchasing 78,125 shares at $0.64, indicating growing confidence in the company's potential.

VolitionRx Limited (NYSE:VNRX - Get Free Report) shares were down 4.3% during mid-day trading on Thursday . The stock traded as low as $0.63 and last traded at $0.64. Approximately 199,690 shares traded hands during trading, an increase of 2% from the average daily volume of 196,287 shares. The stock had previously closed at $0.67.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on VNRX shares. Jones Trading upgraded shares of VolitionRx to a "strong-buy" rating and set a $3.00 target price on the stock in a research note on Tuesday, June 10th. D. Boral Capital reiterated a "buy" rating and set a $5.00 price objective on shares of VolitionRx in a research report on Thursday, July 17th. Finally, Wall Street Zen started coverage on shares of VolitionRx in a research report on Thursday, May 15th. They set a "sell" rating on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $3.50.

VolitionRx Stock Up 0.5%

The company has a fifty day moving average price of $0.69 and a 200-day moving average price of $0.59. The stock has a market capitalization of $66.76 million, a P/E ratio of -1.78 and a beta of 1.26.

Insiders Place Their Bets

In related news, Director Guy Archibald Innes purchased 78,125 shares of the stock in a transaction that occurred on Tuesday, August 5th. The stock was bought at an average cost of $0.64 per share, for a total transaction of $50,000.00. Following the completion of the transaction, the director directly owned 966,814 shares in the company, valued at $618,760.96. This represents a 8.79% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Cameron John Reynolds purchased 78,125 shares of the stock in a transaction that occurred on Tuesday, August 5th. The stock was bought at an average price of $0.64 per share, with a total value of $50,000.00. Following the completion of the transaction, the chief executive officer owned 2,609,847 shares of the company's stock, valued at $1,670,302.08. The trade was a 3.09% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 258,750 shares of company stock valued at $148,475. 10.40% of the stock is currently owned by insiders.

Institutional Trading of VolitionRx

Institutional investors have recently bought and sold shares of the stock. Blair William & Co. IL bought a new stake in VolitionRx in the second quarter worth $30,000. Two Sigma Securities LLC purchased a new stake in shares of VolitionRx during the fourth quarter valued at $29,000. Millennium Management LLC purchased a new stake in shares of VolitionRx during the fourth quarter valued at $36,000. Northern Trust Corp boosted its stake in shares of VolitionRx by 32.0% during the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company's stock valued at $71,000 after purchasing an additional 28,579 shares during the period. Finally, Silverberg Bernstein Capital Management LLC boosted its stake in shares of VolitionRx by 42.8% during the second quarter. Silverberg Bernstein Capital Management LLC now owns 200,782 shares of the company's stock valued at $153,000 after purchasing an additional 60,209 shares during the period. 8.09% of the stock is currently owned by institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.